Kafein ile İlişkili Bozukluklar
Özet
Kafein, dünyada en yaygın tüketilen psikoaktif maddedir ve otonom ile merkezi sinir sistemi üzerinde belirgin klinik etkilere sahiptir. Günlük 100 mg güvenli tüketim olarak önerilirken, günde 250 mg'ın üzeri bağımlılığa, 1 gramın üzeri ise ciddi toksik yan etkilere yol açabilir. Merkezi sinir sisteminde düşük dozlarda adenozin reseptör antagonizması ile uyanıklığı artırıp yorgunluğu azaltırken; yüksek dozlarda anksiyete, uykusuzluk ve intoksikasyona neden olur. DSM-5'te kafein kullanım bozukluğu tanımlanmamış olsa da kafein yoksunluğu ve intoksikasyonu birer tanı olarak kabul edilmiştir. Kafein kullanımı; duygudurum, uyku, yeme bozuklukları ve şizofreni gibi psikiyatrik durumlarla yakından ilişkilidir. Şizofreni hastalarında dopaminerjik aktiviteyi artırarak psikotik belirtileri şiddetlendirebilir. Ayrıca alkol, amfetamin ve esrar gibi bağımlılık yapıcı maddelerle etkileşime girerek bu maddelerin toksik veya bilişsel olumsuz etkilerini değiştirebilir ya da artırabilir. Yeme bozukluğu olan bireyler ise iştah azaltıcı etkisinden ötürü kafeini kötüye kullanabilmektedir. Bu riskler nedeniyle, özellikle anksiyete, uyku ve yeme bozukluğu olan hastalarda kafein tüketiminin rutin olarak sorgulanması ve yüksek tüketimi olan kişilerin tüketimlerini kademeli olarak azaltması önerilmektedir.
Caffeine is the most widely consumed psychoactive substance in the world and has distinct clinical effects on the autonomic and central nervous systems. While a daily intake of 100 mg is recommended as safe, consumption above 250 mg per day can lead to dependence, and exceeding 1 gram can cause severe toxic side effects. In the central nervous system, low doses increase alertness and reduce fatigue through adenosine receptor antagonism, whereas high doses lead to anxiety, insomnia, and intoxication. Although caffeine use disorder is not defined in DSM-5, caffeine withdrawal and intoxication are recognized as diagnoses. Caffeine consumption is closely associated with psychiatric conditions such as mood, sleep, and eating disorders, as well as schizophrenia. In patients with schizophrenia, it can exacerbate psychotic symptoms by increasing dopaminergic activity. Furthermore, it interacts with addictive substances like alcohol, amphetamines, and cannabis, altering or compounding their toxic or cognitive adverse effects. Individuals with eating disorders may misuse caffeine due to its appetite-suppressant effects. Given these risks, evaluating caffeine intake should be a routine part of psychiatric assessments, particularly for patients with anxiety, sleep, and eating disorders, and a gradual reduction is advised for high consumers.
Referanslar
Lean ME, Crozier A. Coffee, caffeine and health: what's in your cup? Maturitas. 2012;72(3):171-2.
Evatt D, Griffiths R. Caffeine. Encyclopedia of Human Nutrition: Elsevier Inc.; 2012. p. 221-7.
Garipağaoğlu M, Kuyrukçu N. Çocuk Sağlığı ve Kafein. Çocuk Dergisi 2009;9(3):110-5.
Coşkunol H. Alkol Bağımlılığı Tanı ve Tedavisi. Ege Üniversitesi Basımevi, Bornova, İzmir. 1996.
Garipağaoğlu M, Kuyrukçu N. Çocuk sağlığı ve kafein. Çocuk Dergisi. 2009;9(3):110-5.
Bızdağlı Y, Tekin A, Şıktar E, et al. Effect Of Caffeine On Exercise Performance: Current Review. Turkish Journal of Sport and Exercise. 2021;23(1):86-101.
Blanchard J, Sawers S. The absolute bioavailability of caffeine in man. European journal of clinical pharmacology. 1983;24(1):93-8.
Cappelletti S, Piacentino D, Sani G, Aromatario M. Caffeine: cognitive and physical performance enhancer or psychoactive drug? Curr Neuropharmacol. 2015;13(1):71-88.
Daly JW, Fredholm BB. Caffeine--an atypical drug of dependence. Drug and alcohol dependence. 1998.
Wang HR, Woo YS, Bahk WM. Caffeine-induced psychiatric manifestations: a review. Int Clin Psychopharmacol. 2015;30(4):179-82.
Martin EA, Nicholson WT, Eisenach JH, et al. Influences of adenosine receptor antagonism on vasodilator responses to adenosine and exercise in adenosine responders and nonresponders. Journal of applied physiology. 2006;101(6):1678-84.
Ferré S, Fuxe K, Von Euler G, et al. Adenosine-dopamine interactions in the brain. Neuroscience. 1992;51(3):501-12.
Kruger A. Chronic psychiatric patients' use of caffeine: pharmacological effects and mechanisms. Psychological Reports. 1996;78(3):915-23.
Boyd GR, Reemtsma H, Grimm DA, Mitra S. Pharmaceuticals and personal care products (PPCPs) in surface and treated waters of Louisiana, USA and Ontario, Canada. Science of the total Environment. 2003;311(1-3):135-49.
Fredholm BB. Adenosine, adenosine receptors and the actions of caffeine. Pharmacology & toxicology. 1995;76(2):93-101.
Coskunol H. Kafein. Karamustafalıoğlu KO (ed.), Temel ve Klinik Psikiyatri içinde. Ankara: Güneş Tıp Kitabevleri Ltd. Şti; 2018. p. 585-590.
Kendrick SF, Day CP. A coffee with your brandy, Sir? Journal of Hepatology. 2007;46(5):980-2.
Donovan J, DeVane C. A primer on caffeine pharmacology and its drug interactions in clinical psychopharmacology. Psychopharmacology Bulletin. 2001;35(3):30-48.
Hancock S, McKim W. Drugs and behavior: An introduction to behavioral pharmacology: Pearson; 2017.
Finnegan D. The health effects of stimulant drinks. Nutrition Bulletin. 2003;28(2):147-55.
J. Boekema MS, GP van Berge Henegouwen, AJPM Smout, P. Coffee and gastrointestinal function: facts and fiction: a review. Scandinavian Journal of Gastroenterology. 1999;34(230):35-9.
Roehrs T, Roth T. Caffeine: sleep and daytime sleepiness. Sleep medicine reviews. 2008;12(2):153-62.
La Vecchia C. Coffee, liver enzymes, cirrhosis and liver cancer. Journal of hepatology. 2005;42(4):444-6.
Shilo L, Sabbah H, Hadari R, Kovatz S, Weinberg U, Dolev S, et al. The effects of coffee consumption on sleep and melatonin secretion. Sleep medicine. 2002;3(3):271-3.
International Food Information Council Foundation Caffeine & Health: Clarifying The Controversies. Washington DC; March 2008.
Winston AP, Hardwick E, Jaberi N. Neuropsychiatric effects of caffeine. Advances in Psychiatric Treatment. 2005;11(6):432-9.
Weng X, Odouli R, Li D-K. Maternal caffeine consumption during pregnancy and the risk of miscarriage: a prospective cohort study. American journal of obstetrics and gynecology. 2008;198(3):279. e1-. e8.
Güleç G, Köşger F, Eşsizoğlu A. DSM-5'te alkol ve madde kullanım bozuklukları. Psikiyatride Güncel Yaklaşımlar. 2015;7(4):448-60.
Scott NR, Chakraborty J, Marks V. Caffeine consumption in the United Kingdom: a retrospective survey. Food Sciences and Nutrition. 1989;42(3):183-91.
Cappelletti S, Daria P, Sani G, et al. Caffeine: cognitive and physical performance enhancer or psychoactive drug? Current neuropharmacology. 2015;13(1):71-88.
Jefferson J. Lithium tremor and caffeine intake: two cases of drinking less and shaking more. The Journal of clinical psychiatry. 1988;49(2):72-3.
Clark I, Landolt HP. Coffee, caffeine, and sleep: A systematic review of epidemiological studies and randomized controlled trials. Sleep medicine reviews. 2017;31:70-8.
Nicholson A, Stone BM. Heterocyclic amphetamine derivatives and caffeine on sleep in man. British Journal of Clinical Pharmacology. 1980;9(2):195.
Brown SL, Salive ME, Pahor M, et al. Occult caffeine as a source of sleep problems in an older population. Journal of the American Geriatrics Society. 1995;43(8):860-4.
Fuxe K, Ferré S, Canals M, et al. Adenosine A2A and dopamine D2 heteromeric receptor complexes and their function. Journal of molecular neuroscience. 2005;26(2):209-20.
Hughes JR, McHugh P, Holtzman S. Alcohol & Drug Abuse: Caffeine and Schizophrenia. Psychiatric Services. 1998;49(11):1415-7.
Lohr JB, Flynn K. Smoking and schizophrenia. Schizophrenia research. 1992;8(2):93-102.
Swanson JA, Lee JW, Hopp JW. Caffeine and nicotine: a review of their joint use and possible interactive effects in tobacco withdrawal. Addictive behaviors. 1994;19(3):229-56.
Zaslove MO, Russell RL, Ross E. Effect of caffeine intake on psychotic in-patients. The British Journal of Psychiatry. 1991;159(4):565-7.
Rush CR, Sullivan JT, Griffiths RR. Intravenous caffeine in stimulant drug abusers: subjective reports and physiological effects. Journal of Pharmacology and Experimental Therapeutics. 1995;273(1):351-8.
Lucas PB, Pickar D, Kelsoe J, et al. Effects of the acute administration of caffeine in patients with schizophrenia. Biological Psychiatry. 1990;28(1):35-40.
Odom-White A, de Leon J. Clozapine levels and caffeine. J Clin Psychiatry. 1996;57(4):175-176.
Ferré S. Caffeine and substance use disorders. Journal of Caffeine Research. 2013;3(2):57.
Ferré S, O'Brien MC. Alcohol and caffeine: the perfect storm. Journal of caffeine research. 2011;1(3):153-62.
Frau L, Simola N, Morelli M. Contribution of caffeine to the psychostimulant, neuroinflammatory and neurotoxic effects of amphetamine-related drugs. Journal of Caffeine Research. 2013;3(2):79-84.
Sousa VC, Assaife-Lopes N, Ribeiro JA, et al. Regulation of hippocampal cannabinoid CB1 receptor actions by adenosine A1 receptors and chronic caffeine administration: implications for the effects of Δ9-tetrahydrocannabinol on spatial memory. Neuropsychopharmacology. 2011;36(2):472-87.
Sousa VC, Ribeiro JA, Sebastião AM. Caffeine and Adenosine Receptor Modulation of Cannabinoid Influence Upon Cognitive Function. Journal of Caffeine Research. 2013;3(2):85-95.
Deal CL. Osteoporosis: prevention, diagnosis, and management. The American journal of medicine. 1997;102(1):35S-9S.
Striegel‐Moore RH, Franko DL, Thompson D, et al. Caffeine intake in eating disorders. International Journal of Eating Disorders. 2006;39(2):162-5.
Krahn DD, Hasse S, Ray A, et al. Caffeine consumption in patients with eating disorders. Psychiatric Services. 1991;42(3):313-5.
Greden JF, Fontaine P, Lubetsky M, et al. Anxiety and depression associated with caffeinism among psychiatric inpatients. The American journal of psychiatry. 1978.
de Freitas B, Schwartz G. Effects of caffeine in chronic psychiatric patients. The American Journal of Psychiatry. 1979.
Mayo K, Falkowski W, Jones C. Caffeine: use and effects in long-stay psychiatric patients. The British Journal of Psychiatry. 1993;162(4):543-5.
